Novel Antimitotic Agent SP-1-39 Inhibits Head and Neck Squamous Cell Carcinoma

Area of Science:

• Oncology
• Cancer Research
• Pharmacology

Background:

• Head and neck cancer (HNC), particularly head and neck squamous cell carcinoma (HNSCC), presents significant management challenges.
• Current HNSCC treatments (surgery, radiation, chemotherapy) are limited, especially in advanced or resistant stages.
• SP-1-39, a novel colchicine-binding site inhibitor (CBSI), has demonstrated efficacy across various cancer types and can overcome drug resistance.

Purpose of the Study:

• To evaluate the preclinical efficacy of SP-1-39 as a potential new treatment for HNSCC.
• To assess SP-1-39's effects on HNSCC cell proliferation, apoptosis, migration, and cell cycle.
• To determine SP-1-39's in vivo anti-tumor activity and safety in an HNSCC xenograft model.

Main Methods:

• In vitro studies using two HNSCC cell lines to assess SP-1-39's impact on proliferation, apoptosis, migration, and cell cycle.
• In vivo studies using a subcutaneous xenograft mouse model (Detroit 562) in NSG mice to evaluate SP-1-39's tumor growth suppression.
• Comparison of SP-1-39's efficacy with paclitaxel in the xenograft model.

Main Results:

• SP-1-39 demonstrated potent in vitro inhibition of HNSCC cell proliferation with low nanomolar IC50 values (1.4–2.1 nM).
• SP-1-39 induced dose-dependent apoptosis, inhibited migration, and caused G2/M cell cycle arrest in HNSCC cells.
• In vivo, SP-1-39 significantly suppressed primary tumor growth in a xenograft model at 2.5 mg/kg without observable toxicity, showing superior efficacy to paclitaxel (10 mg/kg).

Conclusions:

• SP-1-39 exhibits significant preclinical anti-cancer activity against HNSCC.
• SP-1-39 demonstrates a favorable efficacy profile and safety margin in preclinical models.
• SP-1-39 represents a promising therapeutic candidate for further clinical development in HNSCC treatment.